A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Friedreich Ataxia

Interventions

DRUG

DT-216P2

DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.

DRUG

Saline

Normal saline solution will be used as placebo control.

Trial Locations (1)

Nucleus Network, Level 5, 89 Commercial Road, Melbourne